Conversely, while WHO-HAEM5 requires at least 20% blasts to define AML in the absence of an AML-defining genetic lesion, the ICC recognizes an “MDS/AML” overlap group encompassing cases with 10–19% blasts that lack AML-defining genetics, effectively replacing MDS-EB2. Here, MAPRE2 is linked to acute myeloid leukemia.